• Regenxbio Inc (NASDAQ: RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME).

• The data were presented at the American Society of Retina Specialists Annual Meeting.

• RGX-314 is a potential one-time gene therapy under development for wet age-related macular degeneration and DR.

• Of the 15 patients dosed with RGX-314 in Cohort 1, five patients (33%) demonstrated a two-step or greater improvement from baseline on the disease severity scale at three months, compared to zero in the observational control group.

• One patient dosed with RGX-314 had a four-step improvement.

• In the seven patients who had NPDR (DR severity level 47-53) at baseline, three patients (43%) demonstrated a two-step or greater improvement.

• In the eight patients who had PDR (DR severity level over 61) at baseline, two patients (25%) demonstrated a two-step or greater improvement.

• Related: AbbVie, RegenXBio Ink .75B Retinal Gene Therapy Collaboration.

• Price Action: RGNX shares are up 1.07% at $32.01 during the market session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Atai Life Launches Depression-Focused Firm

• NanoVibronix Shares Gain As PainShield Shows Effectiveness In Treating Soft Tissue Pain

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.